Literature DB >> 24229707

Histone H3.3 mutations: a variant path to cancer.

Benjamin T K Yuen1, Paul S Knoepfler.   

Abstract

A host of cancer types exhibit aberrant histone modifications. Recently, distinct and recurrent mutations in a specific histone variant, histone H3.3, have been implicated in a high proportion of malignant pediatric brain cancers. The presence of mutant H3.3 histone disrupts epigenetic posttranslational modifications near genes involved in cancer processes and in brain function. Here, we review possible mechanisms by which mutant H3.3 histones may act to promote tumorigenesis. Furthermore, we discuss how perturbations in normal H3.3 chromatin-related and epigenetic functions may more broadly contribute to the formation of human cancers.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24229707      PMCID: PMC3882088          DOI: 10.1016/j.ccr.2013.09.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  77 in total

1.  A complex Polycomb issue: the two faces of EZH2 in cancer.

Authors:  Hanno Hock
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

Review 2.  Polycomb silencers control cell fate, development and cancer.

Authors:  Anke Sparmann; Maarten van Lohuizen
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

3.  Epigenetic memory of an active gene state depends on histone H3.3 incorporation into chromatin in the absence of transcription.

Authors:  Ray Kit Ng; J B Gurdon
Journal:  Nat Cell Biol       Date:  2007-12-09       Impact factor: 28.824

4.  Nucleosome-depleted chromatin gaps recruit assembly factors for the H3.3 histone variant.

Authors:  Jonathan I Schneiderman; Guillermo A Orsi; Kelly T Hughes; Benjamin Loppin; Kami Ahmad
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

5.  Low frequency of H3.3 mutations and upregulated DAXX expression in MDS.

Authors:  Youmna Attieh; Qi-Rong Geng; Courtney D Dinardo; Hong Zheng; Yu Jia; Zhi-Hong Fang; Irene Gañán-Gómez; Hui Yang; Yue Wei; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2013-05-09       Impact factor: 22.113

6.  H3K36 methylation antagonizes PRC2-mediated H3K27 methylation.

Authors:  Wen Yuan; Mo Xu; Chang Huang; Nan Liu; She Chen; Bing Zhu
Journal:  J Biol Chem       Date:  2011-01-14       Impact factor: 5.157

7.  The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma.

Authors:  Shwetal Mehta; Emmanuelle Huillard; Santosh Kesari; Cecile L Maire; Diane Golebiowski; Emily P Harrington; John A Alberta; Michael F Kane; Matthew Theisen; Keith L Ligon; David H Rowitch; Charles D Stiles
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

8.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

9.  H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?

Authors:  Marco Gessi; Gerrit H Gielen; Jennifer Hammes; Evelyn Dörner; Anja Zur Mühlen; Andreas Waha; Torsten Pietsch
Journal:  J Neurooncol       Date:  2013-01-26       Impact factor: 4.130

10.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

View more
  62 in total

Review 1.  Molecular insights into pediatric brain tumors have the potential to transform therapy.

Authors:  Amar Gajjar; Stefan M Pfister; Michael D Taylor; Richard J Gilbertson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  Functional IRGM polymorphism is associated with language impairment in glioma and upregulates cytokine expressions.

Authors:  Jing Ge; Li Li; Qi Jin; Yu Chen Liu; Ludong Zhao; Hai-Han Song
Journal:  Tumour Biol       Date:  2014-05-24

Review 3.  Examining the impact of gene variants on histone lysine methylation.

Authors:  Capucine Van Rechem; Johnathan R Whetstine
Journal:  Biochim Biophys Acta       Date:  2014-05-23

Review 4.  New insights and challenges in mismatch repair: getting over the chromatin hurdle.

Authors:  Guo-Min Li
Journal:  DNA Repair (Amst)       Date:  2014-04-24

Review 5.  Quantitative proteomic analysis of histone modifications.

Authors:  He Huang; Shu Lin; Benjamin A Garcia; Yingming Zhao
Journal:  Chem Rev       Date:  2015-02-17       Impact factor: 60.622

Review 6.  Point mutations in an epigenetic factor lead to multiple types of bone tumors: role of H3.3 histone variant in bone development and disease.

Authors:  Shigeaki Kato; Takeaki Ishii; Alexander Kouzmenko
Journal:  Bonekey Rep       Date:  2015-07-01

Review 7.  Review of low-grade gliomas in children--evolving molecular era and therapeutic insights.

Authors:  Soumen Khatua; Jason Wang; Veena Rajaram
Journal:  Childs Nerv Syst       Date:  2015-02-27       Impact factor: 1.475

8.  Aberrant Function of the C-Terminal Tail of HIST1H1E Accelerates Cellular Senescence and Causes Premature Aging.

Authors:  Elisabetta Flex; Simone Martinelli; Anke Van Dijck; Andrea Ciolfi; Serena Cecchetti; Elisa Coluzzi; Luca Pannone; Cristina Andreoli; Francesca Clementina Radio; Simone Pizzi; Giovanna Carpentieri; Alessandro Bruselles; Giuseppina Catanzaro; Lucia Pedace; Evelina Miele; Elena Carcarino; Xiaoyan Ge; Chieko Chijiwa; M E Suzanne Lewis; Marije Meuwissen; Sandra Kenis; Nathalie Van der Aa; Austin Larson; Kathleen Brown; Melissa P Wasserstein; Brian G Skotko; Amber Begtrup; Richard Person; Maria Karayiorgou; J Louw Roos; Koen L Van Gassen; Marije Koopmans; Emilia K Bijlsma; Gijs W E Santen; Daniela Q C M Barge-Schaapveld; Claudia A L Ruivenkamp; Mariette J V Hoffer; Seema R Lalani; Haley Streff; William J Craigen; Brett H Graham; Annette P M van den Elzen; Daan J Kamphuis; Katrin Õunap; Karit Reinson; Sander Pajusalu; Monica H Wojcik; Clara Viberti; Cornelia Di Gaetano; Enrico Bertini; Simona Petrucci; Alessandro De Luca; Rossella Rota; Elisabetta Ferretti; Giuseppe Matullo; Bruno Dallapiccola; Antonella Sgura; Magdalena Walkiewicz; R Frank Kooy; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2019-08-22       Impact factor: 11.025

9.  Management of high-grade gliomas in the pediatric patient: Past, present, and future.

Authors:  Magimairajan Issai Vanan; David D Eisenstat
Journal:  Neurooncol Pract       Date:  2014-09-12

Review 10.  Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.

Authors:  Nadejda M Tsankova; Peter Canoll
Journal:  J Neurooncol       Date:  2014-06-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.